BioCopy Chooses Genedata for AI-Powered Multispecific Antibody Discovery
Thursday, July 25, 2024
Cutting-edge biotech builds on best-in-class software to automate R&D workflows for designing novel drug candidates using machine learning approaches
BASEL, Switzerland, July 17, 2024 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that BioCopy, a research-based biotechnology company and innovator in combining artificial intelligence with end-to-end automated protein engineering to generate safe and effective cancer drugs, has chosen Genedata to streamline the discovery and development of next-generation multi-specific biotherapeutics for the treatment of cancer.
Our end-to-end automated engineering lab produces massive amounts of complex data unmatched in the industry that Genedata captures and structures into high-quality and contextualized information to feed into our AI platform. Jörg Birkenfeld, Ph.D., CSO of BioCopy"We brought in Genedata as our data backbone to ensure all information across projects and groups is analyzed in a central platform so that we can speed up the development of cancer drugs," said Jörg Birkenfeld, Ph.D., CSO of BioCopy. "Our end-to-end automated engineering lab produces massive amounts of complex data unmatched in the industry that Genedata captures and structures into high-quality and contextualized information to feed into our AI platform. This is critical for accelerating our research and provides the basis for data-driven design of innovative drug candidates."
BioCopy uses an AI-powered, end-to-end automated platform that enables the development of highly efficient and safe multi-specific biotherapeutics. Using their proprietary technology ValidaTe, BioCopy performs large-scale analyses of the interaction between a multitude of cancer cell markers and potential biotherapeutics. BioCopy's automated engineering lab provides the capacity to combine various functionally distinct molecular components into a single drug candidate based on a building-block assembly method. It also analyzes up to 25,000 novel candidates in parallel for multiple attributes that are critical for the developability of the molecules. This contributes significantly to an accelerated time-to-market for biotherapeutic drug candidates.
The volume and complexity of BioCopy's R&D data led them to choose Genedata Biologics® and Genedata Screener® as their enterprise digital solution to streamline increasingly sophisticated multi-specific antibody engineering workflows. Genedata Biologics is used for designing, registering, tracking, and analyzing candidate molecules, including expression, purification and assay analytics. The platform is fully integrated with BioCopy's laboratory instruments and IT infrastructure to ensure full data traceability and integrity.
"We are pleased that BioCopy builds their AI-centered R&D on Genedata to make their R&D faster and more efficient, helping them deliver cutting-edge therapeutics to patients sooner," said Othmar Pfannes, Ph.D., CEO of Genedata. "Genedata will continue to invest in our foundational platform for AI, providing a solid basis for AI/ML-based drug discovery."
About BioCopy
BioCopy is a Swiss-German biotech company with headquarters in Basel and a state-of-the-art R&D facility in Emmendingen, Germany. The company focuses on drastically accelerating the development of safe and effective next-generation cancer drugs to improve the chance of a cure significantly. BioCopy combines artificial intelligence with its automated end-to-end engineering platform to create biotherapeutics with unrivalled efficacy and safety that are transforming the R&D process in today's pharmaceutical industry. The BioCopy platform generates data sets of high quality and quantity currently unmatched in the industry that are essential to leverage the potential of AI. This synergy reduces the research and development time of next-generation biotherapeutics from approximately three years to 12 months. It will save valuable time in the fight against cancer and significantly reduce the cost of cancer therapeutics.
In the long term, BioCopy will expand its efforts beyond cancer and develop biotherapeutics for immunological and neurological diseases. The company is managed by Dr Matthias Wiedenfels, a proven expert and industry insider in the pharmaceutical and biotechnology industry, not least through his time as CEO of STADA Arzneimittel AG.
http://www.biocopy.com
LinkedIn
About Genedata
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
http://www.genedata.com
LinkedIn | X | YouTube
Contact
Allison Kurz
Genedata
Public Relations
pr@genedata.com
Dr. Claudia Duppé
BioCopy
Director Communications
press@biocopy.com
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
Media Contact
Allison Kurz, Genedata, +41 61 511 84 00, pr@genedata.com, www.genedata.com
View original content to download multimedia:https://www.prweb.com/releases/biocopy-chooses-genedata-for-ai-powered-multispecific-antibody-discovery-302195831.html
SOURCE Genedata
|
|
|
|
|
 |
Weekly Recap: 11 Tech Press Releases You Need to See | Jan 22, 2026
|
|
Sup AI Sets New Benchmark Record with 52.15% on Humanity's Last Exam | Jan 22, 2026
|
|
DEADLINE ANNOUNCED FOR 2026 NEW TOP-LEVEL DOMAIN APPLICATIONS | Jan 22, 2026
|
|
Trigent Partners with WeWork India to Expand its GCC Footprint | Jan 22, 2026
|
|
Skunk Works® and XTEND Expand Joint All Domain Command and Control for Advanced Mission Execution | Jan 22, 2026
|
|
Exia Labs Brings Keystone to the U.S. Navy via DIU's Blue Object Management Challenge | Jan 22, 2026
|
|
Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI | Jan 22, 2026
|
|
Glasswall Brings Defense-Level File Sanitization to Every Government Agency and Business Using Microsoft 365 | Jan 22, 2026
|
|
Genpact Named a Leader in ISG Provider Lens(TM) 2025 for Insurance GCCs and Agentic AI Services | Jan 22, 2026
|
|
Buyers Edge Platform Appoints Jaime Selga to Lead Expansion Across the Middle East, Africa & Asia | Jan 22, 2026
|
|
|
